Chinese Journal of Tissue Engineering Research ›› 2018, Vol. 22 ›› Issue (25): 3963-3968.doi: 10.3969/j.issn.2095-4344.0940

Previous Articles     Next Articles

Effect of Erxian Decoction on proliferation and bone differentiation of bone marrow mesenchymal stem cells in ovariectomized rats

Wu Qi1, 2, Liu Bo1, 2, Chen Zhi1, Xu Peng1, 2   

  1. 1Jiangxi University of Traditional Chinese Medicine, Nanchang 330004, Jiangxi Province, China; 2Jiangxi Provincial Key Laboratory of Pharmacology of Traditional Chinese Medicine, Nanchang 330004, Jiangxi Province, China
  • Revised:2018-05-19 Online:2018-09-08 Published:2018-09-08
  • Contact: Liu Bo, M.D., Jiangxi University of Traditional Chinese Medicine, Nanchang 330004, Jiangxi Province, China; Jiangxi Provincial Key Laboratory of Pharmacology of Traditional Chinese Medicine, Nanchang 330004, Jiangxi Province, China
  • About author:Wu Qi, Jiangxi University of Traditional Chinese Medicine, Nanchang 330004, Jiangxi Province, China; Jiangxi Provincial Key Laboratory of Pharmacology of Traditional Chinese Medicine, Nanchang 330004, Jiangxi Province, China
  • Supported by:

    the National Natural Science Foundation of China, No. 81560723; the Natural Science Foundation of Jiangxi Province, No. 20151BAB205072; and the Science and Technology Project of Jiangxi Provincial Health and Family Planning Commission, No. 2015B027

Abstract:

BACKGROUND: Some studies have shown that bone marrow mesenchymal stem cells (BMSCs) are involved in bone formation. Erxian Decoction can treat osteoporosis, but its relationship with BMSCs in ovariectomized rats is not yet clear.
OBJECTIVE: To reveal the relationship between Erxian Decoction and BMSCs by exploring the effect of Erxian Decoction on proliferation and differentiation of BMSCs in rats with osteoporosis.
METHODS: Sprague-Dawley rats were randomly divided into six groups: sham group, model group, estrogen group, high-dose Erxian Decoction group, middle-dose Erxian Decoction group and low-dose Erxian Decoction groups. Ovariectomy was performed to establish rat osteoporosis models in all the groups except the sham group. The rats in the sham group and model group were given normal saline via gavage, and those in the estrogen group were fed with estradiol valerate (0.08 g/L). Rats in the high-, middle- and low-dose groups were given high (1.2 g/mL), middle (0.8 g/mL) and low (0.4 g/mL) concentrations of Erxian Decoction extracts at a dose of 10 mL/kg, for 90 continuous days. BMSCs were isolated by whole bone marrow adherent method, MTT method was used to draw the growth curve of BMSCs, alkaline phosphates kit was used to detect alkaline phosphatase activity, and alizarin red staining was used to detect calcium nodules in BMSCs.
RESULTS AND CONCLUSION: Compared with the model group, high-, middle -, and low-dose Erxian Decoction significantly increased the proliferative capacity of BMSCs in ovariectomized rats (P < 0.01), and significantly improved alkaline phosphatase activity in BMSCs of ovariectomized rats (P < 0.05, P < 0.0.1). The highest activity of alkaline phosphatase in BMSCs was found after treatment with middle-dose Erxian Decoction (P < 0.01). High- and middle-dose Erxian Decoction also promoted the formation of calcium nodules in BMSCs (P < 0.01). These results indicate that to improve BMSCs proliferation and osteogenic differentiation in ovariectomized rats is one of the intrinsic mechanisms of Erxian Decoction in the treatment of osteoporosis.

中国组织工程研究杂志出版内容重点:干细胞;骨髓干细胞;造血干细胞;脂肪干细胞;肿瘤干细胞;胚胎干细胞;脐带脐血干细胞;干细胞诱导;干细胞分化;组织工程

Key words: Mesenchymal Stem Cells, Alkaline Phosphatase, Tissue Engineering

CLC Number: